TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples